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Abstract
Background: Gastric foveolar hyperplastic polyps (GFHPs) are common findings in clinical practice. GFHPs
commonly arise in a background of chronic atrophic gastritis, including autoimmune gastritis (type A gastritis), and
have a potential risk of malignant transformation.
Case presentation: In 2005, a 55-year-old Japanese woman underwent upper endoscopy at another hospital and
was found to have a pedunculated polyp (10 mm in diameter) on the greater curvature of the lower gastric body.
On biopsy, the polyp was diagnosed as a GFHP. Nine years later, the polyp had grown to 20 mm in diameter, and
the biopsy specimen taken at this time showed tubular adenocarcinoma. On admission to our hospital, the serum
Helicobacter Pylori (H. pylori) immunoglobulin G antibody and stool H. pylori antigen were both negative. Anti-gastric
parietal cell antibody was positive, as was the anti-intrinsic factor antibody, and the fasting serum gastrin level was
markedly increased. In 2014, en bloc resection of the pedunculated polyp was performed by endoscopic
submucosal dissection. The final histological diagnosis was adenocarcinoma of the stomach with submucosal and
lymphatic invasion. Subsequently, additional radical distal gastrectomy was performed. At the latest follow-up
(12 months postoperatively), no recurrence was noted.
Conclusions: We here reported a rare case of malignant transformation of GFHP arising in a context of type A
gastritis. To our knowledge, there are no previous reports on malignant transformation of GFHP with submucosal
and lymphatic invasion arising in a background of type A gastritis in the English literature. Further, there is currently
no effective treatment other than endoscopic or surgical treatment for such cases. Given the potential risk of
malignant transformation due to hypergastrinemia, we consider that endoscopic treatment should be considered
as a first-line therapy when a malignant growth is suspected.
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Background
Gastric foveolar hyperplastic polyps (GFHPs) are com-
mon findings in clinical practice. They do not regress or
disappear spontaneously and are associated with a risk
of malignant transformation in 0.6–4.5 % of cases [1–5].
GFHPs commonly arise in a background of chronic atro-
phic gastritis, including both type B gastritis, associated
with Helicobacter Pylori (H. pylori) infection, as well as
type A gastritis (autoimmune gastritis) [6]. In Japan, type
B gastritis accounts for > 76 % of all gastritis cases [7, 8].
A previous study reported that eradication of H. pylori
led to regression and disappearance of gastric hyperplas-
tic polyps in approximately 70 % of patients [9]. In this
context, H. pylori eradication therapy is recommended
in Japan. However, H. pylori eradication therapy is not
effective for all cases, particular for GFHPs arising in a
background of autoimmune gastritis (type A gastritis).
With the increased prevalence and effectiveness of H.
pylori eradication therapy, the clinical impact of auto-
immune gastritis, and thereby also of GFHPs, is rising.
There is currently no effective treatment other than
endoscopic or surgical treatment for GFHPs arising in a
background of H. pylori-negative type A gastritis. There-
fore, endoscopic treatment is recommended as the first-
line therapy when a malignant growth is suspected.
Case presentation
In November 2005, a 55-year-old Japanese woman under-
went upper endoscopy at another hospital and was found
to have a pedunculated polyp, measuring 10 mm in diam-
eter, on the greater curvature of the lower gastric body
(Fig. 1a). On biopsy, it was diagnosed as a GFHP. At the
moment of the first diagnosis, there was only an endo-
scopic report and the endoscopic appearance could be
compatible with an atrophic mucosa. In January 2013,
upper endoscopy was repeated, which revealed that the
polyp had grown to 12 mm in diameter with a slightly
rounded head (Fig. 1b). Biopsy was not performed at the
time.
In June 2014, the patient underwent positron emission
tomography-computed tomography to evaluate the treat-
ment effect on her right breast cancer, for which she had
undergone surgery and received chemotherapy and radi-
ation therapy at the age of 53 years. There was an abnormal
accumulation in the lower gastric body (Fig. 2). Subsequent
upper endoscopy showed that the polyp had grown to
20 mm in diameter, and the surface of the head was slightly
reddish and tense (Fig. 1c). The biopsy specimen obtained
from the head of the polyp was histologically diagnosed as
tubular adenocarcinoma and was determined to be unre-
lated to the breast cancer. It was suggested that the polyp
became malignant during the nine years of follow-up, and
the patient was referred to our institution for further evalu-
ation and treatment.
Physical examination
On physical examination, scars from the right breast
mastectomy with bilateral axillary lymph node dissection
were noted. No other remarkable findings were observed.
Laboratory data (Table 1)
No abnormalities were found in the blood counts or
liver and renal function tests. The serum H. pylori im-
munoglobulin G antibody and stool H. pylori antigen were
both negative. The anti-gastric parietal cell antibody was
positive (80-fold increase), as was the anti-intrinsic factor
antibody. The fasting serum gastrin level was markedly in-
creased at > 3000 pg/ml (normal range, < 200 pg/ml). The
serum pepsinogenI level and pepsinogen I/II ratio were
both low (Table 1).
Fig. 1 Endoscopy findings. a. In 2005, a pedunculated polyp measuring approximately 10 mm in diameter was observed on the greater curvature
of the lower gastric body. The surface of the polyp was slightly reddish. On biopsy, the lesion was diagnosed as a hyperplastic foveolar polyp.
b. In 2013, the pedunculated polyp on the greater curvature of the lower gastric body had grown to 12 mm in diameter. The head of the polyp
was more rounded compared to the image taken in 2005. c. In 2014, the pedunculated polyp on the greater curvature of the lower gastric body
had grown to 20 mm in diameter. The head of the polyp was slightly reddish, more rounded, and tense
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Medication
The patient was not taking any medication at the time.
Positron emission tomography-computed tomography
(July 2014) (Fig. 2)
A well-circumscribed mass with a maximum stan-
dardized uptake value of 2.7 was observed in the lower
gastric body. There were no findings suggesting the pres-
ence of gastrinoma.
Clinical course
In August 2014, en bloc resection of the pedunculated
polyp, measuring 20 mm in diameter, on the greater
curvature of the lower gastric body was performed by
endoscopic submucosal dissection (Fig. 3).
Histopathological examination showed tumor lesions,
which had well-defined borders with hyperplastic glands
(Fig. 4a, b). The tumor lesions were strongly positive for
p53 and Ki-67, while the hyperplastic lesions were not
(Fig. 4c). Submucosal invasion was observed in the stalk,
with an invasion depth of 300 μm (Fig. 4d). In D2-40-
positive and cluster of differentiation 34-negative lymph
ducts, cells with acidophilic cytoplasm and large nuclei
were observed. The cells were positive for keratin, indi-
cating lymphovascular invasion (Fig. 4e). As a result the
final histological diagnosis was adenocarcinoma of the
stomach, tubular adenocarcinoma > papillary adenocar-
cinoma, size of resected lesion 20 mm in size, submuco-
sal invasion of 0.3 mm, venous invasion (-), lymphatic
invasion (+).
Fig. 2 Positron emission tomography-computed tomography findings. A well-circumscribed mass was observed in the lower gastric body, with a
maximum standardized uptake value of 2.7
Table 1 Laboratory data
Hematological analysis Value Unit Blood chemistry Value Unit
White blood cell count 4800 /μl TP 7.3 g/dl
Hemoglobin 11.9 g/dl Alb 4.4 g/dl
Hematocrit 37.8 % T-bil 0.81 mg/dl
Platelets 19.5 × 104 /μl D-bil 0.24 mg/dl
AST 34 U/L
Tumor markers ALT 25 U/L
Carcinoembryonic antigen 1.3 ng/ml LDH 197 U/L
Cancer antigen-15-3 17.1 U/ml γ-GTP 16 IU/l
BUN 11 mg/dl
Anti‐parietal cell antibody 80 fold Cre 0.55 mg/dl
Anti-intrinsic factor antibody + Gastrin >3000 pg/dl
Pepsinogen I 7.6 ng/ml Vit B12 208 pg/ml
Pepsinogen II 16.3 ng/ml
Pepsinogen I/II/ ratio <0.5 ng/ml
Abbreviations: TP total protein, Alb albumin, T-bil total bilirubin, d-bil direct bilirubin, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate
dehydrogenase, γ-GTP gamma-glutamyl transpeptidase, BUN blood urea nitrogen, Cre creatinine, Vit vitamin
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Consequently, additional radical distal gastrectomy
was performed. Examination of the surgical specimens
showed a scar resulting from the endoscopic submucosal
dissection on the anterior wall of the gastric body. There
were no residual tumor cells or lymph node metastasis.
Examination of the background mucosa showed that the
proper gastric glands in the pyloric region were pre-
served, while those in the mucosa of the gastric body
were atrophic and showed intestinal metaplasia and
pseudo-pyloric metaplasia (Fig. 5). In the OLGA staging
system, the corpus and the antrum were scored as 2 and
0, respectively, indicating stageII gastritis at the time of
surgery [10, 11]. Chromogranin A staining revealed
enterochromaffin-like cell hyperplasia (linear hyperplasia
and micronodular hyperplasia) (Fig. 5b, arrows indicate
micronodular hyperplasia). H. pylori infection was nega-
tive (Fig. 5).
Conclusions
The classification of chronic gastritis into types A and B
was proposed by Strickland et al. [12]. However, cur-
rently, there are no established diagnostic criteria for the
diagnosis of type A gastritis. Traditionally, type A gastri-
tis has been diagnosed based on the anti-gastric parietal
and anti-intrinsic factor antibody findings, presence of
corpus-predominant atrophic gastritis, and serum gas-
trin levels, with Ban et al. stating that asymptomatic type
A gastritis could be diagnosed by anti-gastric parietal
antibody [13]. The prevalence of autoimmune gastritis is
unclear [13, 14]. In the early stage, the diagnosis of type
A gastritis is difficult even with a biopsy, since the symp-
toms of anemia due to malabsorption of vitamin B12 and
iron usually develop at a later stage. In the present case,
we considered that the patient was not infected with H.
pylori, because her serum H. pylori immunoglobulin G
antibody, stool H. pylori antigen, and histological examin-
ation were all negative. On the other hand, the patient was
positive for anti-gastric parietal cell and anti-intrinsic fac-
tor antibodies, and had a markedly elevated level of serum
gastrin and reduced pepsinogenI level and pepsinogenI/II
ratio. Moreover, the patient had corpus-predominant atro-
phic gastritis, OLGA stageII, and enterochromaffin-like
cell hyperplasia. Taken together, these findings led to the
diagnosis of type A chronic atrophic gastritis. Although
we did not have the sufficient histological data from the
first endoscopy performed in 2005, mild corpus atrophy
was detected at that time. Rugge et al. reported that in
116 patients with autoimmune gastritis, 87 cases (75.0 %)
remained and 25 cases (21.6 %) progressed to a higher
OLGA gastritis stage during a mean follow-up period of
54 months (range, 24–108 months) [11]. Considering the
gastritis stage in 2014, the present case can thus be specu-
lated to have been at stageI orII in 2005. Type A gastritis
is characterized by the presence of hypergastrinemia asso-
ciated with reduced gastric acid secretion. Gastrin is a
peptide hormone synthesized and released mainly from G
Fig. 3 Endoscopic submucosal dissection. En bloc endoscopic submucosal dissection was performed for the pedunculated polyp, measuring
20 mm in diameter, on the greater curvature of the lower gastric body
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cells in the gastric antrum, which plays a role in the regu-
lation of gastric acid secretion and gastrointestinal motility
[15]. Furthermore, it is known to exert trophic actions on
digestive cells [16, 17]. In the present patient, it was sug-
gested that the GFHP had grown during the nine-year
follow-up period, owing to her hypergastrinemia; her
serum gastrin level was > 3000 pg/ml before undergoing
distal gastrectomy, but decreased to 74 pg/ml 48 h after
the surgery.
The process of cancer development is considered to be
a multistage process (hyperplasia ➔ dysplasia ➔ carcin-
oma); that is, as the polyp grows and becomes more dys-
plastic, the risk of cancer increases [2, 5, 18, 19]. The
most important risk factors of malignant transformation
in chronic atrophic gastritis include age over 50 years,
severe atrophy, and the presence of intestinal metaplasia
extension [20]. The present patient fit the first and third
risk factors. Rugge et al. reported that the risk of cancer
was restricted to case of high-risk gastritis stage (OLGA
stages III-IV) and that it was associated mainly with
concomitant H. pylori infection [11]. However, malig-
nant transformation in type A gastritis associated with
hypergastrinemia might be induced at an earlier gastritis
stage. Several genetic alterations have been revealed in
hyperplastic polyps, including abnormal expression of
tumor suppressor p53, K-ras mutations, and microsatellite
instability [18, 21]. Shibahara et al. conducted a study of
gastric hyperplastic polyps and reported that increased ex-
pression of p53 was observed in dysplastic and carcinoma
cells but not in the normal or hyperplastic cells, and that
the expression of Ki67 was higher in the carcinoma and
dysplastic cells than in the hyperplastic cells. They sug-
gested that examinations of p53 and Ki67 were useful
markers of malignant transformation of gastric hyperplas-
tic polyps [22]. Yao et al. and Zea-Iriarte et al. also sug-
gested that p53 plays an important role in the malignant
transformation of gastric hyperplastic polyps [19, 23]. In
the present case, the expression of p53 was strongly posi-
tive in the carcinoma cells and Ki67 was positive in ap-
proximately 50 % of the carcinoma cells, while these
stainings were much decreased in the non-transformed
cells (Fig. 4b).
The reported incidence of malignant transformation of
GFHP ranges from 0.6 to 4.5 % [1–5], and Fujino et al.
reported that the mean diameter of GFHPs with malig-
nant transformation was as large as 23.4 ± 10.2 mm [24].
Fig. 4 Histological findings. a. Hematoxylin and eosin (HE) staining. b. High magnification image of the boxed area. c. HE, p53, and Ki-67 stainings
of the border between the hyperplastic glands and the tumor glands. The tumor lesions were strongly positive for p53 and Ki-67. d. Submucosal
invasion in the stalk, with an invasion depth of 300 μm (MM, muscularis mucosae; SM, submucosal layer). e. HE, cluster of differentiation 34
(CD34), D2-40, and keratin staining. In CD34-negative and D2-40-positive lymph ducts, keratin-positive cells with acidophilic cytoplasm and large
nuclei were observed, indicating lymphatic invasion (arrows)
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Regarding the histological type, most previously reported
cases were differentiated adenocarcinomas, while a few
were poorly-differentiated adenocarcinomas or signet
ring cell carcinomas [25–28]. The GFHP in the present
patient was 20 mm in diameter and histologically diag-
nosed as differentiated adenocarcinoma (Fig. 4).
The diagnostic criteria of malignant GFHP proposed by
Nakamura et al. in 1985 are as follows [29]: 1) coexistence
of benign and malignant parts in the same polyp; 2) exist-
ence of sufficient evidence that the benign area has previ-
ously been a benign polyp; and 3) existence of sufficient
cellular and structural atypia in the malignant area to be
diagnosed as cancer. The patient in the present study met
these criteria and was therefore diagnosed with malignant
transformation of GFHP over nine years. GFHPs with
carcinoma have been reported to have the following
macroscopic characteristics: pedunculated form, larger size
(>20 mm), reddish color, irregular or nodular surface,
white-coated, and bleeding tendency [2, 23, 25, 30, 31].
Our patient displayed four of these macroscopic features,
including pedunculated form, a diameter > 20 mm, growth
tendency, and a white-coated lesion.
It has been reported that magnifying endoscopy with
narrow band imaging is useful for the diagnosis of can-
cer [32–34]; however, it is not sufficiently useful for
diagnosing malignant transformation of gastric hyper-
plastic polyps [23]. Ahn et al. reported that GFHPs
measuring 10 mm or larger in diameter should be endo-
scopically resected [35], whereas Tanabe et al. reported
the disappearance of a 20 mm hyperplastic polyp with
malignant transformation after H. pylori eradication
therapy [36]. The lesion in the present patient was diag-
nosed as tubular adenocarcinoma on biopsy. Endoscopic
estimation of the invasion depth of the carcinoma was
difficult; hence, endoscopic submucosal dissection, a
minimally invasive procedure, was performed. The re-
sults showed a submucosal invasion depth of 0.3 mm
and lymph duct invasion. Subsequently, we performed
additional distal gastrectomy and lymph node dissection.
There was no distant metastasis, and we considered that
complete removal of the tumor was achieved. At the
time of this report, the patient has been followed-up for
12 months after surgery with no recurrence.
To our knowledge, there are only a few previous cases,
limited to Japan, of malignant GFHP with submucosal
invasion requiring surgical treatment [37, 38], and there
are no previous reports on malignant transformation of
GFHP with submucosal invasion and lymphatic invasion
arising in a background of type A gastritis in the English
literature. Thus, the present case is considered very rare
and to provide valuable information. Importantly, there
is currently no effective treatment other than endoscopic
or surgical treatment for GFHPs, secondary to type A
gastritis. Moreover, as this type of polyp has a potential
risk of malignant transformation due to hypergastrine-
mia, endoscopic or surgical treatment should be consid-
ered when malignant transformation is suspected.
Abbreviation





Availability of data and materials
Not applicable.
Fig. 5 Examination of the background mucosa. a. The proper gastric
glands in the pyloric region were preserved. There was no atrophic
change. b. The proper gastric glands in the gastric body. The mucosa
was atrophic and showed intestinal metaplasia and pseudo-pyloric
metaplasia. Muc6 is a gastric pyloric gland- type secretory mucin.
Enterochromaffin-like cell hyperplasia (linear hyperplasia and micro-
nodular hyperplasia (arrows)) was revealed by chromogranin A staining
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